Novo Nordisk A/S (NVO)
38.64
+0.46
(+1.20%)
USD |
NYSE |
Oct 09, 16:00
38.60
-0.04
(-0.10%)
After-Hours: 20:00
Novo Nordisk Free Cash Flow (Quarterly) : 6.362B for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.362B |
| March 31, 2026 | 1.780B |
| December 31, 2025 | -5.447B |
| September 30, 2025 | 4.822B |
| June 30, 2025 | 757.78M |
| March 31, 2025 | 4.268B |
| December 31, 2024 | -567.19M |
| September 30, 2024 | 4.605B |
| June 30, 2024 | 5.397B |
| March 31, 2024 | 772.24M |
| December 31, 2023 | -998.46M |
| September 30, 2023 | 4.401B |
| June 30, 2023 | 3.150B |
| March 31, 2023 | 3.606B |
| December 31, 2022 | -17.49M |
| September 30, 2022 | 2.737B |
| June 30, 2022 | 3.053B |
| March 31, 2022 | 3.288B |
| December 31, 2021 | -961.12M |
| September 30, 2021 | 3.161B |
| June 30, 2021 | 3.788B |
| March 31, 2021 | 1.581B |
| December 31, 2020 | -1.842B |
| September 30, 2020 | 1.810B |
| June 30, 2020 | 3.379B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.224B |
| December 31, 2019 | 303.77M |
| September 30, 2019 | 2.135B |
| June 30, 2019 | 1.849B |
| March 31, 2019 | 1.044B |
| December 31, 2018 | 491.96M |
| September 30, 2018 | 1.349B |
| June 30, 2018 | 2.127B |
| March 31, 2018 | 1.133B |
| December 31, 2017 | 509.72M |
| September 30, 2017 | 1.685B |
| June 30, 2017 | 1.250B |
| March 31, 2017 | 1.491B |
| December 31, 2016 | 1.219B |
| September 30, 2016 | 1.874B |
| June 30, 2016 | 1.921B |
| March 31, 2016 | 939.73M |
| December 31, 2015 | 1.124B |
| September 30, 2015 | 1.654B |
| June 30, 2015 | 1.615B |
| March 31, 2015 | 499.33M |
| December 31, 2014 | 937.11M |
| September 30, 2014 | 2.001B |
| June 30, 2014 | 1.329B |
| March 31, 2014 | 600.03M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| AstraZeneca PLC | 1.885B |
| GSK Plc | 2.511B |
| Johnson & Johnson | 7.295B |
| Eli Lilly & Co. | 4.475B |
| Merck & Co., Inc. | 4.477B |